Latent virus reactivation risk and biological drugs: chronic inflammatory and immune-mediated disorders.
Psoriasis vulgaris, psoriatic arthritis and rheumatoid arthritis are chronic inflammatory and immune-mediated disorders, widely distributed in the population and induced by several environmental factors in genetically predisposed individuals. Different therapies are currently used to treat these diseases. Since these pathologies are characterized by an altered production of proinflammatory cytokines and chemokines, and biological therapy is based on the development of monoclonal antibodies or recombinant proteins against these molecules, this therapy represents an important option. Nevertheless, it was recently reported that biological agents have been associated with serious life-threatening infections. This article aims to summarize literature data on viral reactivation risk that clinicians need to take into account when selecting the most appropriate biological therapy for such patients.